Join the National Institute of Child Health and Human Development (NICHD)’s Dr. Tracey Rouault for a free webinar on a compound, TEMPOL, that could potentially be formulated into a preventative and oral treatment for COVID-19.

When SARS-CoV-2 enters a host, the cells replicate it and viral particles invade the nearby healthy cells. This happens because SARS-CoV-2’s genome is catalyzed by RNA-dependent RNA Polymerase (RdRP). This triggers an inflammatory response and can lead to transmission to another host. A therapeutic that can stop this replication from happening is imperative.

Inventors at the National Cancer Institute and NICHD have discovered that the nitroxide antioxidant, TEMPOL, interferes with RdRP’s assembly and activity and can reduce the viral replication in vitro. This shows that TEMPOL could be used as an antiviral to treat people that have a SARS-CoV-2 infection. The competitive advantages of using TEMPOL as a COVID-19 therapeutic are that it targets replication of SARS-CoV-2, it is inexpensive, accessible, and has low cytotoxicity.

If you are interested in reading more about this technology, please visit the abstract.

This webinar will take place on Wednesday, November 17, 2021 at 11am EST. Please register or view more information here.